NTRS
52
-3
PFE
33
-3
UA
24
-5
HSIC
57
-3
NTAP
55
6
QCOM
59
-3
EW
51
-2
MSI
55
-2
BBY
42
-4
C
67
-4
MMC
48
-5
GILD
50
-6
PYPL
41
-13
A
62
-2
RRC
46
3
D
48
-2
REGN
48
2
AKAM
37
-5
IFF
63
-3
NKE
52
-4
NTRS
52
-3
PFE
33
-3
UA
24
-5
HSIC
57
-3
NTAP
55
6
QCOM
59
-3
EW
51
-2
MSI
55
-2
BBY
42
-4
C
67
-4
MMC
48
-5
GILD
50
-6
PYPL
41
-13
A
62
-2
RRC
46
3
D
48
-2
REGN
48
2
AKAM
37
-5
IFF
63
-3
NKE
52
-4
Financhill
Back

Entrada Therapeutics 10K Form

Sell
33

TRDA
Entrada Therapeutics

Last Price:
$6.54
Seasonality Move:
15.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TRDA News And Ratings

See the #1 stock for the next 7 days that we like better than TRDA

TRDA Financial Statistics

Sales & Book Value

Annual Sales: $210.8M
Cash Flow: $-39.7M
Price / Cash Flow: 0
Annual Sales: $11.00
Price / Book: 0.6

Profitability

EPS (TTM): 0.81000
Net Income (TTM): $24.8M
Gross Margin: --
Return on Equity: 6.3%
Return on Assets: 4.66%

Entrada Therapeutics Earnings Forecast

Key Entrada Therapeutics Financial Ratios

  • The Research & Development expenses have been 59.45% of Revenue.
  • The Net Earning history of TRDA is 31.13% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Entrada Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TRDA
Website: entradatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 21.88
Quick Ratio: 20.86

Price-to-Earnings

Trailing P/E Ratio: 3.9
Forward P/E Ratio: 0

TRDA Technical Analysis vs Fundamental Analysis

Sell
33
Entrada Therapeutics (TRDA) is a Sell

Is Entrada Therapeutics a Buy or a Sell?